School of Medicine


Showing 1-20 of 72 Results

  • Andrei Iagaru

    Andrei Iagaru

    Professor of Radiology (Nuclear Medicine)

    Current Research and Scholarly InterestsCurrent research projects include:
    1) PET/MRI and PET/CT for Early Cancer Detection
    2) Targeted Radionuclide Therapy
    3) Clinical Translation of Novel PET Radiopharmaceuticals;

  • David Iberri

    David Iberri

    Clinical Assistant Professor, Medicine - Hematology

    BioDr. Iberri is a medical oncologist and hematologist who specializes in the treatment of hematologic malignancies. His clinical practices runs the gamut of malignant and non-malignant hematologic disorders including acute and chronic leukemias, multiple myeloma and lymphomas, and bleeding and thrombotic disorders. He is actively involved in clinical trials evaluating novel agents in hematologic malignancies. His research interests are in the development and application of biomarkers to select patients most likely to benefit from therapy.

  • Kenzo Ichimura

    Kenzo Ichimura

    Postdoctoral Scholar, Pulmonary and Critical Care Medicine

    BioMy long-term goal as a physician-scientist is to develop therapeutic strategies for right heart failure by elucidating its pathophysiology.

    I graduated from Kyushu University, School of Medicine in Fukuoka, Japan in 2008. Following a residency program at Aso Iizuka Hospital, I finished fellowship in Emergency Medicine (1 year) and Cardiovascular Medicine (2 years). My clinical expertise is general cardiology, cardiac catheterization, echocardiography, and cardiac critical care.

    After my clinical training, I started my research career working towards a Ph.D. under the mentorship of Dr. Kensuke Egashira. During my Ph.D., I published two papers focusing on the development of novel therapeutics for acute myocardial infarction and pulmonary arterial hypertension. Through this research experience, I developed skills in modeling and assessing cardiovascular disease in both small (rodents) and large animals (pigs)

    In 2017, I was appointed as an Assistant Professor and attending physician in the Department of Emergency and Critical Care Medicine at Kyushu University Hospital. During this period, I learned that right heart failure was one of the most devastating conditions with no treatment options in patients with pulmonary hypertension, congenital heart disease, and patients on long-term mechanical ventricular assist devices. I also continued my research with a research grant funded by the Japanese Society for the Promotion of Science.

    In 2019, I decided to further expand my research field into right heart failure and joined Dr. Edda Spiekerkoetter’s lab at Stanford University as a postdoctoral fellow. I am currently focusing on the role of BMPR2 in the cardiomyocytes, the structural changes in the right ventricle under pressure overload, and the development of right ventricle-targeting therapy in pulmonary hypertension.

  • Juliana Idoyaga

    Juliana Idoyaga

    Assistant Professor of Microbiology and Immunology

    Current Research and Scholarly InterestsThe Idoyaga Lab is focused on the function and biology of dendritic cells, which are specialized antigen-presenting cells that initiate and modulate our body’s immune responses. Considering their importance in orchestrating the quality and quantity of immune responses, dendritic cells are an indisputable target for vaccines and therapies.

    Dendritic cells are not one cell type, but a network of cells comprised of many subsets or subpopulations with distinct developmental pathways and tissue localization. It is becoming apparent that each dendritic cell subset is different in its capacity to induce and modulate specific types of immune responses; however, there is still a lack of resolution and deep understanding of dendritic cell subset functional specialization. This gap in knowledge is an impediment for the rational design of immune interventions. Our research program focuses on advancing our understanding of mouse and human dendritic cell subsets, revealing their endowed capacity to induce distinct types of immune responses, and designing novel strategies to exploit them for vaccines and therapies.

  • Irogue I Igbinosa

    Irogue I Igbinosa

    Masters Student in Epidemiology and Clinical Research, admitted Autumn 2022

    BioIrogue Igbinosa, MD is a Maternal-Fetal Medicine fellow at Stanford University. She graduated from the University of Houston and earned her medical degree at Baylor College of Medicine. She subsequently completed her residency in Obstetrics and Gynecology Residency at Louisiana State University School of Medicine Baton Rouge. After residency, she was an AAMC-CDC Public Health Policy Fellow able to serve in the CDC Emergency Operations Center and contribute to research for health care providers regarding the management of the Zika virus in pregnant persons. Dr. Igbinosa's current research interests include severe maternal morbidity and mortality, health disparities and equity, anemia in pregnancy, infectious diseases, and clinical trials.

  • Francie Igboabuchi

    Francie Igboabuchi

    Life Science Rsch Prof 1, Stem Cell Bio Regenerative Med Institute

    Current Role at StanfordLife Science Research Professional I

  • Debra M. Ikeda, M.D.

    Debra M. Ikeda, M.D.

    Professor of Radiology (Breast Imaging), Emerita

    Current Research and Scholarly InterestsMy research interests are mammography positioning, tomosynthesis (DBT) cancer detection and diagnosis, MRI, DWI, MRI-guided breast biopsy, breast cancer recurrence, tattoo/ fiducial/wire localization of axillary lymph nodes, breast cancer and FDG PET-CT imaging, artifical intelligence/deep learning, breast density, density notification legislation, COVID-19 effects on Breast Imaging Centers and personnel

  • Gentaro Ikeda

    Gentaro Ikeda

    Postdoctoral Scholar, Cardiovascular Medicine

    BioDr. Ikeda is a physician-scientist who develops innovative diagnostic and therapeutic modalities for patients with cardiovascular disease. Based on his clinical experience as a cardiologist, he has become aware of major clinical shortcomings, specifically in the current pharmaceutical therapies for myocardial infarction (MI) and chronic heart failure (HF). Some evidence-based drug therapies, including β-blockers, ivabradine, and renin-angiotensin-aldosterone antagonists are difficult to apply to critical patients due to adverse side effects. Drugs that have shown efficacy in basic animal experiments have failed to show significant benefits in clinical trials. To address these problems, he moved to academia to conduct translational research. During his graduate training in the Egashira Lab, he focused on drug delivery systems (DDS) that target mitochondria in animal models of MI. He obtained advanced skills in molecular biology, mitochondrial bioenergetics, and animal surgery. He realized the importance of translational research and the great potential of DDS to overcome many clinical problems. He developed nanoparticle-mediated DDS containing cyclosporine for the treatment of patients with MI. He published a first-author paper and received academic awards for his novel science. Since becoming a postdoctoral fellow in the Yang Lab, he has continued to build upon his previous training in translational research. He is currently developing an innovative therapy, namely, extracellular vesicles-mediated mitochondrial transfer for mitochondria-related diseases such as heart failure and mitochondrial disease.

  • Fumiaki Ikeno

    Fumiaki Ikeno

    Program Director (U.S) Japan Biodesign, Stanford Biodesign, Medicine - Med/Cardiovascular Medicine

    BioProgram Director (U.S) Japan Biodesign, Stanford Biodesign
    Researcher Cardiovascular Medicine, Stanford University
    Faculty of Japan Reach, CARE (Center for Asian Health Research and Education) , Stanford University
    Co-Director of Asia, SPARK Global, Stanford SPARK , Stanford University


    Dr. Ikeno is a Researcher, Cardiovascular Medicine, Stanford University. In this role, he is responsible for pre clinical studies including GLP for medical devices and also regenerative medicines for cardiovascular diseases. Currently, he is devoting himself to the international regulatory project between Japan and the United States, also known as "Harmonization by Doing", whose focus is to collaborate with regulatory agencies such as FDA, PMDA/MHLW, academia and industries for improving the regulatory process in the 2 largest medtech markets. Dr. Ikeno also devoted himself to found Japan biodesign program which is a collaborative program with University of Tokyo, Osaka University, Tohoku University, Japan Federation Medical Device Association, Ministry of Education Japan and Stanford biodesign program. Currently, Dr. Ikeno serves as the Program Director (US) for Japan Biodesign. Dr. Ikeno is co-founder and board member of US-Japan MedTech Frontier which is a non-profit cooperate to make a trans-pacific eco-system of medical device between Japan and USA.

    After 9 years clinical practice as an interventional cardiologist and Family Doctor in rural areas of Japan, Dr. Ikeno came to Stanford as a Researcher and completed his Biodesign Certificate Program. Being part of the ecosystem in Silicon Valley, Dr. Ikeno participated in more than 200 medtech projects and 50 GLP studies as well as in the analysis of clinical trials for cardiovascular medicine (BARI2D, FAME, ReOPEN etc). His other academic consortium projects include Peripheral Academic Research Consortium, Global Consensus Working Group of Optical Coherence Tomography, and Japan-US consensus document for the treatment of critical limb ischemia.

    Over the last decade, Dr. Ikeno has served as an advisor for medical device industries and currently serves as a chief medical officer of an incubation fund specific for medtech (Medventure Partners, Inc, Tokyo) as a spin-off from Innovation Network Corporation of Japan (INCJ) that is the largest government and private partnership fund in Japan. He is also serving as a chair of cardiovascular working group of APAN (Asian Pacific Advanced Network) that contributes the remote education, research activities, and tele-health using a specialized internet network. Dr.Ikeno is also serving as consulting faculty/lecturer roles in several universities in Japan including University of Tokyo, Osaka University, Tsukuba University etc. Dr. Ikeno has authored over 70 peer reviewed publications and textbooks and has been invited to lecture at international medical conferences. Dr. Ikeno is a council member of U.S.- Japan Council which is a non-profit organization by Japanese American. He is serving as a mentor for START-X MED which is an accelerating program for Stanford related entrepreneurs in medical fields.

    Contact Information


    Falk CVRC CV007
    300 Pasteur Drive
    Palo Alto, CA 94305-5406